Dawn of CAR-T cell therapy in autoimmune diseases
Copyright © 2024 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license..
ABSTRACT: Chimeric antigen receptor (CAR)-T cell therapy has achieved remarkable success in the treatment of hematological malignancies. Based on the immunomodulatory capability of CAR-T cells, efforts have turned toward exploring their potential in treating autoimmune diseases. Bibliometric analysis of 210 records from 128 academic journals published by 372 institutions in 40 countries/regions indicates a growing number of publications on CAR-T therapy for autoimmune diseases, covering a range of subtypes such as systemic lupus erythematosus, multiple sclerosis, among others. CAR-T therapy holds promise in mitigating several shortcomings, including the indiscriminate suppression of the immune system by traditional immunosuppressants, and non-sustaining therapeutic levels of monoclonal antibodies due to inherent pharmacokinetic constraints. By persisting and proliferating in vivo, CAR-T cells can offer a tailored and precise therapeutics. This paper reviewed preclinical experiments and clinical trials involving CAR-T and CAR-related therapies in various autoimmune diseases, incorporating innovations well-studied in the field of hematological tumors, aiming to explore a safe and effective therapeutic option for relapsed/refractory autoimmune diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Chinese medical journal - (2024) vom: 12. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Yuxin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 13.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1097/CM9.0000000000003111 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371025303 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371025303 | ||
| 003 | DE-627 | ||
| 005 | 20240413233505.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/CM9.0000000000003111 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1374.xml |
| 035 | |a (DE-627)NLM371025303 | ||
| 035 | |a (NLM)38613216 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Yuxin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dawn of CAR-T cell therapy in autoimmune diseases |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. | ||
| 520 | |a ABSTRACT: Chimeric antigen receptor (CAR)-T cell therapy has achieved remarkable success in the treatment of hematological malignancies. Based on the immunomodulatory capability of CAR-T cells, efforts have turned toward exploring their potential in treating autoimmune diseases. Bibliometric analysis of 210 records from 128 academic journals published by 372 institutions in 40 countries/regions indicates a growing number of publications on CAR-T therapy for autoimmune diseases, covering a range of subtypes such as systemic lupus erythematosus, multiple sclerosis, among others. CAR-T therapy holds promise in mitigating several shortcomings, including the indiscriminate suppression of the immune system by traditional immunosuppressants, and non-sustaining therapeutic levels of monoclonal antibodies due to inherent pharmacokinetic constraints. By persisting and proliferating in vivo, CAR-T cells can offer a tailored and precise therapeutics. This paper reviewed preclinical experiments and clinical trials involving CAR-T and CAR-related therapies in various autoimmune diseases, incorporating innovations well-studied in the field of hematological tumors, aiming to explore a safe and effective therapeutic option for relapsed/refractory autoimmune diseases | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Dong, Minghao |e verfasserin |4 aut | |
| 700 | 1 | |a Chu, Yunhui |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Luoqi |e verfasserin |4 aut | |
| 700 | 1 | |a You, Yunfan |e verfasserin |4 aut | |
| 700 | 1 | |a Pang, Xiaowei |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Sheng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Luyang |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Lian |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Lifang |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Chuan |e verfasserin |4 aut | |
| 700 | 1 | |a Tian, Daishi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Chinese medical journal |d 1979 |g (2024) vom: 12. Apr. |w (DE-627)NLM000002755 |x 2542-5641 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:12 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/CM9.0000000000003111 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 12 |c 04 | ||